Our lead program focuses on the treatment of patients with recurrent or refractory Ewing’s sarcoma. Vigil utilizes the patient’s own cancer cells to create a fully personalized cancer immunotherapy with the goal to activate the patient’s own T-cells against their cancer cells.
We believe Vigil has several key features and advantages which differentiate it from other cancer immunotherapies:
When those cells are reintroduced back into the patient, these two modifications are designed to help activate the immune system to detect and kill any cancer cells that may remain locally and in circulation.
All together, the goal is to stimulate the existing components of the immune system with the intent to improve their anti-tumor responses. Vigil enhances specific functions that assist in cancer antigen recognition and dampen other functions that cancer cells often employ to evade the immune system.